Company: ATRA
Filing Date: 2025-03-03
Form Type: 8-K
Source: 0000950170-25-030832
Chunk: 0

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-03
Form: 8-K
Item: Item 2.05
Chunk 0
---
Item 2.05 Costs Associated with Exit or Disposal Activities.

On March 3, 2025, the Company announced a reduction in its workforce that will impact approximately 50% of its current employees following the Company’s decision to discontinue all development activities for ATA3219 and ATA3431, including all CAR T clinical studies evaluating ATA3219 and pause both ATA3219 and ATA3431 programs. The Company expects to substantially complete the workforce reduction by June 2025. The Company expects to recognize approximately $3.0 million in total for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash charges. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction. Additional details will be provided in the Company’s Quarterly Report on Form 10-Q for the period ending March 31, 2025.

Item 9.01 Financial Statements and Exhibits.